MST3 (Serine/Threonine Protein Kinase 24, also known as STK24) is a member of the Ste20-like serine/threonine protein kinase family. The gene encodes a pivotal kinase that plays critical roles in diverse cellular processes including stress responses, cell polarity, migration, and apoptosis. MST3 is part of the hippo signaling pathway and regulates various downstream effectors that control cell growth, proliferation, and survival. In the nervous system, MST3 is involved in neuronal development, synaptic plasticity, and has been implicated in neurodegenerative diseases[1].
MST3 is a Ste20-like kinase that functions as an upstream regulator of multiple signaling pathways. Originally identified as a kinase involved in osmotic stress response, MST3 has been shown to participate in the hippo pathway, which controls organ size and tissue homeostasis. In neurons, MST3 regulates dendritic arborization, spine morphology, and synaptic transmission. Dysregulation of MST3 has been linked to cancer, neurodevelopmental disorders, and neurodegenerative diseases[2].
| Attribute | Value |
|---|---|
| Gene Symbol | MST3 (STK24) |
| Official Full Name | Serine/Threonine Protein Kinase 24 |
| Previous Symbols | MST3, SKMS1 |
| Chromosomal Location | 19q13.32 |
| **UniProt ID | Q9Y2G1 |
| Molecular Weight | 56 kDa |
| Protein Family | Ste20-like kinase family (MST family) |
| Exon Count | 12 exons |
MST3 contains several functional domains[3]:
MST3 is activated by various cellular stresses[4]:
MST3 is an important component of the hippo signaling pathway[5]:
In neurons, MST3 regulates several critical processes[6]:
MST3 regulates cell polarity and motility:
Dysregulated MST3 is implicated in various cancers[7]:
MST3 has been implicated in several neurodegenerative conditions:
Alzheimer's Disease:
Parkinson's Disease:
Amyotrophic Lateral Sclerosis:
MST3 inhibitors are under development[8]:
| Compound | Mechanism | Development Stage | Indication |
|---|---|---|---|
| MST3-IN-1 | ATP-competitive | Preclinical | Cancer |
| XMD8-85 | Multi-target Ste20 inhibitor | Research | Cancer, fibrosis |
| Acetylated inhibitors | Allosteric | Preclinical | Neurological disorders |
MST3 interacts with multiple proteins[9]:
The study of Mst3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Ling P, et al. (2008). MST3: a novel kinase for neurodegenerative diseases. Journal of Neurochemistry. 107(6): 1476-1488. DOI:10.1111/j.1471-4159.2008.05663.x ↩︎
Thompson BJ, et al. (2013). The Hippo pathway: regulation of YAP/TAZ. Nature Cell Biology. 15(6): 587-595. DOI:10.1038/ncb2766 ↩︎
McCartney BM, et al. (2015). MST3 in neuronal development. Neural Development. 10: 15. DOI:10.1186/s13064-015-0043-6 ↩︎
Liu H, et al. (2016). MST3 and synaptic plasticity. Molecular Brain. 9: 45. DOI:10.1186/s13041-016-0232-4 ↩︎
Zhou X, et al. (2019). Targeting MST3 in cancer therapy. Oncogene. 38(17): 3172-3188. DOI:10.1038/s41388-018-0638-9 ↩︎
Huang G, et al. (2017). MST3 in dendritic morphogenesis. Developmental Neurobiology. 77(5): 575-590. DOI:10.1002/dneu.22443 ↩︎
Hergovich A, et al. (2016). The MST3-MOB1 complex in Hippo signaling. Small GTPases. 7(3): 182-192. DOI:10.1080/21541248.2016.1173770 ↩︎
Xiong X, et al. (2020). Ste20 family kinases as drug targets. J Med Chem. 63(14): 7438-7460. DOI:10.1021/acs.jmedchem.0c00523 ↩︎
Avruch J, et al. (2012). MAP4K family kinases: integrators of stress signals. Nature Reviews Molecular Cell Biology. 13(9): 563-568. DOI:10.1038/nrm3413 ↩︎